Background and purpose: In patients with subjective cognitive decline, we assessed whether small vessel disease was associated with clinical progression and cognitive decline. Methods: We included 334 patients with subjective cognitive decline. Follow-up was 3±2 years. Results: Fifty-three (16%) patients progressed clinically to mild cognitive impairment (MCI) or dementia. White matter hyperintensities (WMH) were associated with clinical progression and with annual decline on memory, attention, executive functioning, and global cognition. Microbleeds and lacunes were not associated with clinical progression or cognitive decline. Conclusion: In patients with subjective cognitive decline, patients with WMH are at increased risk of clinical progression and cognitive decline.
Introduction
A substantial part of patients who are admitted to a memory clinic have subjective complaints that cannot be objectified by cognitive testing. Increasing evidence indicates that the subjective experience of cognitive decline may reflect an early stage of actual cognitive decline. 1 The term subjective cognitive decline (SCD) has been introduced to refer to these patients. 2 Patients labelled with SCD may present with markers for small vessel disease (SVD), such as white matter hyperintensities (WMH), microbleeds or lacunes. 3 SVD is among the most important causes of cognitive decline and the term vascular cognitive impairment (VCI) has been proposed to capture all forms of cognitive impairment that are attributable to any type of cerebrovascular disease. 4 It is currently unknown whether SVD relates to clinical progression in SCD. We assessed whether SVD is associated with clinical progression and cognitive decline.
Methods
From the Amsterdam Dementia Cohort, 5 we included all patients who came to our memory clinic because of their cognitive complaints and who were considered to have SCD, 2 with a baseline visit between 2000-2013, an available baseline MRI, and at least one year of follow-up (n=344). The local medical ethics committee approved the study. All patients provided written informed consent. WMH, microbleeds, and lacunes were rated on baseline MRI.
Follow-up took place by clinical routine visits in which subject history, cognitive testing, and a general physical and neurologic examination were repeated. Clinical progression was defined as progression to mild cognitive impairment (MCI) or any cause of dementia. Cognitive decline was assessed using repeated neuropsychological evaluation.
Kaplan-Meier curves and Cox proportional-hazard models were used to assess the predictive value of WMH, microbleeds, and lacunes for clinical progression. Linear mixed models were used to estimate effects on cognitive performance over time. Detailed methods are provided in the online-only Data Supplement. Mild, moderate, and severe WMH were associated with clinical progression in unadjusted models (table 1; figure 1). After adjustment mild and severe WMH remained associated. In unadjusted models, the presence of 5 or more microbleeds conferred an increased risk for clinical progression (model 1; figure 1). However, microbleeds and lacunes were not associated with clinical progression in adjusted models. A multivariate model yielded no independent associations. There was no significant interaction for WMH*MTA. 
Results

Discussion
Half of the patients with SCD had SVD to some extent, but severe SVD was rare. Although the majority of the patients with SVD remained stable over 3 years, patients with severe WMH had a 4-fold higher risk to show clinical progression to MCI or dementia, compared with patients without WMH. In addition, increasing WMH severity was associated with decline on memory, attention, executive functioning, and global cognition. These associations were independent of age and MTA; two factors that previously have been pointed out as strong predictors for MCI and dementia. [6] [7] [8] [9] Our results seem in line with findings from the LADIS study, in which a heterogeneous population of non-disabled elderly with WMH was included. 10 We are, however, the first to show this in patients presenting with SCD to a memory clinic.
A major strength of this study is the longitudinal design with substantial follow-up in a well-characterized set of patients with SCD. A limitation is that groups with severe SVD and groups that converted to dementia were rather small. In addition, whereas SVD is generally assumed to represent vascular pathology, associations with degenerative processes have been reported as well. 4 SVD may in itself drive clinical progression in a cascade of events that eventually leads to dementia, 11 or it may co-exist with AD pathology and by that lowering the threshold for clinical symptoms. Recently Jack et al 12 proposed an AD biomarker model to better understand Alzheimer pathology in relation to clinical symptoms. Our finding of an independent association between WMH and clinical progression might argue for a role for vascular pathology as well.
Our findings may also have implications for the VCI criteria 4 that do not yet include SCD in the spectrum of cognitive impairment. Including patients with SCD into the concept of VCI will not only allow anticipation on prognosis, but will also increase awareness for prevention and treatment. figure I ). Patients with follow-up were older than patients without follow-up (62±10 vs. 59±11, p<0.01), but both groups were comparable with regard to all other aspects. The work-up included physical and neurologic examination, extensive neuropsychological testing, laboratory tests, electroencephalography (EEG), and brain magnetic resonance imaging (MRI). Presence of hypertension, hypercholesterolaemia, and diabetes mellitus was determined based on self-reported medical history and medication use. In a multidisciplinary meeting, diagnoses were made by consensus. When patients presented with cognitive complaints, but cognitive and laboratory investigations were normal, and criteria for mild cognitive impairment (MCI), dementia, or any other neurologic or psychiatric disorder were not met, patients were labelled as having SCD. Follow-up took place by clinical routine visits to our memory clinic in which subject history, a general physical and neurologic examination were repeated. Two hundred sixty-two patients (78%) underwent at least one follow-up neuropsychological assessment (see supplemental figure I MRI protocol and assessment MRI scans were obtained at 1.0T (n=184), 1.5T (n=25) or 3.0T scanner (n=125). The scan protocol included T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR), and gradient echo T2*-weighted images and was essentially unchanged over the years. The rater was blinded to the patients' clinical data. WMH were assessed on the FLAIR sequence using the Fazekas scale, with scores from 0 to 3 (none, punctuate, early confluent, and confluent). 8 Microbleeds were defined as small round foci of hypointense signal, up to 10mm in brain parenchyma on T2*-weighted images. Microbleed count was categorized into 0, 1, 2-4, >5 microbleeds, in line with previous reports. 9 Lacunes were defined as deep lesions (3-15mm) with CSF-like signal on all sequences. To account for the skewed distribution lacune count was categorized into 0, 1, 2, >3 lacunes. Medial temporal lobe atrophy (MTA) was rated using a 5-point rating scale (0-4). 10 The mean of left and right MTA scores was dichotomized into MTA absent (<1.5) or MTA present (≥1.5).
Data analyses
Statistical analyses were performed using SPSS 20.0. Baseline characteristics were compared using Student t-test for continuous data and Chi 2 -test for categorical variables.
Cox proportional-hazard models were used to assess the predictive value of the SVD makers (i.e. WMH, microbleeds, and lacunes, in categories) for clinical progression to MCI or all-cause dementia. The first model unadjusted and the second model with adjustment for age, sex, MTA, and MRI field strength. Results are presented as hazard ratios (HR) with 95% confidence intervals (CI), with the first category (no WMH/no microbleeds/no lacunes) as reference category. Next we inserted the SVD markers as continuous variables in the models to investigate the p trend . To test independent effects, a multivariate analysis was performed including all SVD markers simultaneously. For significant models we investigated whether MTA presence modified the effects by adding an interaction-term (MTA*SVD marker) to the corresponding model. Kaplan-Meier curves were plotted for clinical progression with separate lines for the severity categories of the SVD markers. Differences between the curves were assessed using log-rank tests.
Missing neuropsychological data were handled by multiple imputations of individual test scores. 11 Fifteen imputed data sets were created. All baseline neuropsychological data were standardized into z-scores and follow-up z-scores were calculated relative to baseline z-scores. For each of the cognitive domains, the mean zscores for the corresponding tests were calculated. TMT A, TMT B, and Stroop scores were inverted by computing -1×z-scores, because higher scores imply a worse performance. Linear mixed models were used to estimate effects of SVD markers on cognitive performance over time. This method was chosen because it allows for inter-individual differences in number of assessments and for variability in time intervals between assessments. In addition, it takes all available time points into account. We used WMH, microbleeds, and lacunes as categorical predictors in models adjusted for age, sex, education, MTA and MRI field strength. Each model included terms for time, the SVD marker, the interaction of the SVD marker×time, and covariates. Outcome measures were compound z-scores for memory, attention, executive functioning, language, and global cognitive functioning. Beta±standard error (β±SE) for the interaction SVD marker*time represents the association between each SVD marker at baseline and annual change in test performance. Next, we inserted the SVD markers as continuous variables in the models to investigate the p trend . To investigate independent effects, a multivariate analysis was performed inserting all SVD markers simultaneously. 
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